Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Johan Samanta

Neurology Phoenix, AZ Medical Doctor

NPI 1487653739 CMS profile 249270

7500 N Dreamy Draw Dr, Suite 133, Phoenix, AZ 85020

Open in the dashboard

General payments

$145,607

1,062 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$56,940 paid to institutions, not to them · program years 2022–2025

Through program year 2023, Johan Samanta of Phoenix, AZ is reported in the CMS Open Payments database as having received $145,607 across 1,062 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $56,940 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $21,293 178
2022 General $33,556 266
2021 General $27,350 218
2020 General $27,648 192
2019 General $35,761 208

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Johan Samanta
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Johan Samanta were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Johan Samanta Neurology median Middle half National median
2019 $35,761 $474 $118–$2,177 $163
2020 $27,648 $367 $82–$2,309 $114
2021 $27,350 $438 $104–$2,547 $132
2022 $33,556 $442 $103–$2,388 $149
2023 $21,293 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Neurocrine Biosciences, Inc. $74,290 145 payments
  2. Acorda Therapeutics, Inc $45,233 107 payments
  3. Teva Pharmaceuticals USA, Inc. $4,413 69 payments
  4. Sunovion Pharmaceuticals Inc. $3,796 25 payments
  5. AbbVie, Inc. $3,521 85 payments
  6. ACADIA Pharmaceuticals Inc $1,812 135 payments
  7. Jazz Pharmaceuticals Inc. $1,653 7 payments
  8. Medtronic, Inc. $1,541 33 payments
  9. US WorldMeds, LLC $1,201 52 payments
  10. Amneal Pharmaceuticals LLC $1,135 63 payments
  11. Other $7,013 341 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $89,668 57 payments
  2. Consulting Fee $27,795 9 payments
  3. Food and Beverage $20,452 947 payments
  4. Travel and Lodging $7,672 44 payments
  5. Education $21 5 payments
Products named General payments · program years 2019–2023
  1. INGREZZA Neuropsychiatry $44,467 73 payments
  2. INBRIJA $44,303 59 payments
  3. ONGENTYS Neurology $12,043 24 payments
  4. INGREZZA Neurology $7,533 37 payments
  5. INGREZZA Neurology $6,660 23 payments
  6. AUSTEDO $4,023 43 payments
  7. KYNMOBI $3,575 23 payments
  8. DUOPA $2,916 51 payments
  9. Ongentys Neuropsychiatry $2,273 23 payments
  10. RYTARY $1,135 63 payments
  11. Other $14,323 713 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

1,062 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record